Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
Abstract Asciminib, a first‐in‐class BCR‐ABL1 inhibitor that works by Specifically Targeting the ABL Myristoyl Pocket (STAMP), is a new treatment option for patients with chronic myeloid leukemia who no longer benefit from currently approved tyrosine kinase inhibitors. In vitro, asciminib reversibly...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Pukapuka |
| I whakaputaina: |
Wiley,
2022-06-01T00:00:00Z.
|
| Ngā marau: | |
| Urunga tuihono: | Connect to this object online. |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
| Tau karanga: |
A1234.567 |
|---|---|
| Tārua 1 | Wātea |